---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000048"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T16:07:26.878157+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcutis CCO Ken Lock resigns; Ayisha Jeter named interim CCO

## Summary
- Ken Lock, SVP and CCO since Oct 2019, resigns effective June 2, 2023 to attend to personal matters.
- Ayisha Jeter, VP of Market Access since June 2020, appointed interim CCO.
- Company has commenced search for a permanent chief commercial officer.
- Lock led commercialization of ZORYVE (roflumilast) cream 0.3% for plaque psoriasis.

## SEC filing metadata
- accession: 0001787306-23-000048
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/0001787306-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/arqt-20230522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000048
- JSON: https://secwatch.observer/filing/0001787306-23-000048.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000048.txt

## Key facts
- Executive change
  Ayisha Jeter was appointed as Interim Chief Commercial Officer at Arcutis Biotherapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Commercial Officer
  source text: The Company has commenced a search for a permanent chief commercial officer and has appointed Ayisha Jeter, who has served as the Company’s Vice President of Market Access since joining the Company in June 2020, as interim chief commercial officer during the transition period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/0001787306-23-000048-index.htm
- Executive change
  Kenneth Lock resigned as Senior Vice President and Chief Commercial Officer at Arcutis Biotherapeutics, Inc..
  - Action: resigned
  - Role: Senior Vice President and Chief Commercial Officer
  source text: On May 22, 2023, Kenneth Lock notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as Senior Vice President and Chief Commercial Officer of the Company, effective as of June 2, 2023, to attend to personal matters.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/0001787306-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.